Overview of BUCCOLAM

What is BUCCOLAM? — Overview and Key Facts

Property	Description
Active ingredient	Midazolam
Form	Oromucosal solution (buccal solution)
Pharmacological class	Benzodiazepine derivative, Antiepileptic drug
General purpose	Emergency resolution of acute, prolonged convulsive episodes
Origin	Synthetic compound

What Type of Medicine is BUCCOLAM?

BUCCOLAM is a specialized prescription-only medicine that is classified as a direct-acting antiepileptic drug used strictly for acute management. The core substance, Midazolam, is a synthetic compound chemically categorized as a benzodiazepine derivative. Functionally, the drug is primarily classified as a potent Central Nervous System (CNS) depressant, which is the basis for its role as an immediate rescue medication. Its rapid action is effective in terminating acute seizures, and it is used in pediatric patients diagnosed with epilepsy.

Form and Composition: The Buccal Solution

The composition of BUCCOLAM is a monotherapy, containing only the Midazolam substance, typically supplied as the hydrochloride salt, within an aqueous vehicle. The product's key differentiator is its unique dosage form: an oromucosal solution, commonly known as a buccal solution, supplied in a pre-filled syringe for precise delivery. This specialized design distinguishes it from intravenous or rectal formulations of similar agents. This buccal/oromucosal route facilitates the rapid and predictable entry of Midazolam into the bloodstream, a quality recognized as essential for acute seizure intervention.

General Purpose as an Emergency Treatment

The general therapeutic purpose of BUCCOLAM is to provide emergency treatment designed to achieve the immediate and swift resolution of convulsive episodes. This rapid effect is achieved because Midazolam quickly enhances the inhibitory action of the brain's natural calming messenger, Gamma-aminobutyric acid (GABA). This rapid calming of overactive electrical impulses is necessary to terminate the seizure quickly. The fast absorption achieved via the buccal route facilitates the necessary speed of onset required for this crucial intervention in a neutral, non-hospital environment.

Regulatory References

What side effects are possible with BUCCOLAM?

Possible Side Effects and Safety Information

The safety profile for Midazolam (BUCCOLAM) is structured around its established action as a Central Nervous System (CNS) depressant, according to regulatory documentation. Adverse reactions are officially categorized by their frequency of occurrence, separating common effects from those that are rare but clinically significant.

Officially Classified Adverse Reactions

Adverse effects are grouped into system-organ classes based on official reports:

Classification	Examples of Documented Effects
Common	Somnolence, sedation, headache, nausea, vomiting, hiccup, respiratory depression
Rare	Apnoea (cessation of breathing), cardiac arrest, paradoxical reactions (e.g., aggression, hostility)
Not Known	Dependence (physical and psychological), withdrawal symptoms, agitation

Serious Safety Considerations

The most serious safety concerns documented are related to the respiratory system. Respiratory depression and apnoea are listed as potential severe adverse reactions. The risk of cardiac arrest is also noted, though classified as a rare event. The medicine may also cause anterograde amnesia, which is a documented impairment of memory for events immediately following administration.

Population-Specific Safety Notes

Regulatory safety information specifies increased caution for certain populations. Older adults and patients with renal or hepatic impairment are identified as groups potentially more sensitive to the drug's effects, including enhanced CNS and respiratory depression. Use is restricted or contraindicated in individuals with severe respiratory insufficiency or severe hepatic impairment. Furthermore, the co-administration of BUCCOLAM with other CNS depressants is noted to increase the risk of severe sedation and respiratory adverse events.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for BUCCOLAM

Category	Official Regulatory Statement
Documented overdose presentations:	Pronounced Central Nervous System (CNS) depression, manifesting as somnolence, confusion, loss of consciousness, unsteadiness, and impaired coordination.
Physiological systems affected (as stated in label):	The respiratory system (e.g., respiratory depression, slow/shallow breathing, apnea) and the cardiovascular system (e.g., hypotension/low blood pressure, cardiac arrest).
Dose-related or exposure-related factors:	Life-threatening incidents are more likely, especially when higher doses are given or in patients with breathing difficulties.
Population-specific overdose notes:	Elderly patients and those with chronic respiratory insufficiency are at greater risk of respiratory depressant effects. Treatment of infants aged 3 to 6 months must be limited to supervision by a healthcare professional where resuscitation equipment is available.
Emergency-response statements (as written in official documents):	Seek immediate medical assistance if signs of overdose are observed. Call an ambulance immediately if the seizure has not stopped within 10 minutes or if the patient's breathing slows down or stops.
When immediate medical help is required (label-derived phrasing only):	Immediate medical help is required if the seizure does not stop within 10 minutes or if breathing slows down or stops (e.g., slow or shallow breathing, blue lips).

Overdose Classifications (High-Level)

Category	Official Regulatory Statement
Severity classification (as defined in official documents):	Overdose can lead to life-threatening incidents including respiratory arrest and cardiac arrest, sometimes resulting in death or permanent neurologic injury.
Regulatory basis:	Information is based on the safety and emergency sections of government-authorized prescribing information (e.g., SmPC/Prescribing Information).
Overdose-context constraints:	Treatment is generally symptomatic and supportive. The benzodiazepine antagonist Flumazenil may be used by a clinician to reverse the central effects, but continuous monitoring is necessary.

Connection to the overall overdose profile: Official regulatory documents define the overdose profile of BUCCOLAM through the expected escalation from CNS depression to potential life-threatening cardiorespiratory collapse. The profile strictly mandates immediate emergency action when core symptoms of excessive sedation or respiratory distress are observed, or when the intended seizure-stopping effect is not achieved within a regulator-specified timeframe. Management is defined by supportive measures and intensive monitoring.

Therapeutic Uses of BUCCOLAM

What BUCCOLAM Treats: Main Uses and Benefits

The primary role of BUCCOLAM is to provide supportive relief during acute neurological events, focusing on quick access to symptomatic assistance for patients with epilepsy. Its specific indication is the treatment of prolonged, acute, convulsive seizures in patients who have been diagnosed with epilepsy.

BUCCOLAM is indicated for the immediate cessation of acute convulsive episodes that are prolonged or are occurring in clusters. The medication is considered relevant for use when there is a risk of a seizure progressing into status epilepticus, a severe, continuous seizure state. This formulation offers the benefit of being a rescue medication for use in non-hospital settings by trained caregivers, such as parents. This capability helps make immediate intervention available during a crisis.

The main indications covered are prolonged convulsive seizures, acute repetitive seizures, and seizure clustering.

“The primary therapeutic benefit is the interruption of the ongoing, uncontrollable muscular contractions, which generally helps limit the overall duration of the severe seizure event.”

Emergency Termination of Prolonged Convulsive Seizures

BUCCOLAM is applied across therapeutic domains involving heightened symptoms, which may assist with maintaining functional stability during symptomatic periods. The benefit is the interruption of the acute neurological event, which generally helps limit the overall duration of the severe seizure event.

Quick Fact: Relief for Convulsive Seizures The medication plays a role in managing symptoms related to increased neurological or muscular activity, offering symptomatic support during difficult episodes.

Regulatory References

European Medicines Agency (EMA) product information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use BUCCOLAM — Official Regulatory Information

The eligibility for BUCCOLAM (midazolam) is strictly defined by regulatory authorities based on age, physiological state, and pre-existing medical conditions.

Category	Official Regulatory Statement
Populations for whom use is allowed:	Infants, toddlers, children, and adolescents from 3 months to less than 18 years [1.2, 2.3]. Adults are also included in the indication in some regions/doses [2.3].
Populations for whom use is contraindicated:	Individuals with hypersensitivity to midazolam, benzodiazepines, or any excipients [1.2, 2.3]. Patients with Myasthenia gravis, Severe respiratory insufficiency, Sleep apnoea syndrome, and Severe hepatic impairment are absolutely prohibited from use [1.2, 2.3].
Age-related eligibility rules:	Use Not Established: Children aged 0 to 3 months (safety and efficacy have not been established) [2.3]. Special Caution: Adults over 60 years of age are considered a high-risk group [1.3].
Condition-specific eligibility rules:	Use with caution in patients with chronic renal failure, impaired hepatic function (non-severe), impaired cardiac function, and chronic respiratory insufficiency [1.3, 2.1]. Patients with a medical history of alcohol or drug abuse should be avoided [1.3].
Pregnancy and lactation eligibility status:	Pregnancy: May be used if clearly necessary, but the risk for the newborn must be considered if administered in the third trimester [1.3]. Breastfeeding: It is not necessary to stop breast-feeding following a single dose [1.3].

Eligibility Classifications (High-Level)

Classification	Official Regulatory Wording
Eligibility severity classification:	The three main classifications are Contraindicated (prohibited), Use with caution (conditional restriction), and Use not established (lack of approval) [1.3, 2.3].
Eligibility-context constraints:	Use in infants 3 to 6 months of age is limited to a hospital setting where monitoring and resuscitation equipment are available [1.2, 2.3].

Connection to the overall eligibility profile:

The regulatory profile defines who can receive BUCCOLAM by establishing strict mandatory exclusions (contraindications) based on specific organ dysfunction and co-morbidities. It limits the approved population by age range (from 3 months), while simultaneously imposing explicit conditional use (restriction) for the youngest approved infants and stating that use is not established for those below the minimum age [1.2, 2.3].

What should I know about interactions with other medicines?

BUCCOLAM (midazolam) interacts with other medicinal products through two primary mechanisms: its metabolism by the CYP3A4 enzyme system and its central nervous system (CNS) depressant activity.

Pharmacokinetic Interactions (CYP3A4)

Midazolam is metabolized predominantly by the CYP3A4 enzyme. Medicines that inhibit this enzyme, such as azole antifungals (e.g., ketoconazole, fluconazole) and macrolide antibiotics (e.g., erythromycin, clarithromycin), can substantially increase the concentration and prolong the effects of midazolam. Conversely, CYP3A4 inducers (e.g., St John's Wort) can decrease midazolam plasma concentrations and reduce its effect. Careful monitoring and potential dose adjustment are recommended when co-administering these agents.

Pharmacodynamic Interactions (CNS Depression)

The co-administration of BUCCOLAM with other CNS depressants can lead to enhanced sedation, respiratory depression, coma, and death. This category includes:

Opioid analgesics (e.g., fentanyl)
Alcohol (consumption must be avoided)
Other sedative/hypnotic agents and anaesthetics
Certain antiepileptics (e.g., phenytoin)
Muscle relaxants (e.g., baclofen)

Grapefruit juice also reduces the clearance of midazolam and potentiates its action, and should be avoided.

Mechanism of Action

BUCCOLAM contains midazolam, a highly lipophilic compound that rapidly crosses the blood-brain barrier to target the central nervous system (CNS). Within the CNS, midazolam functions as a positive allosteric modulator of the gamma-aminobutyric acid type A ( GABA A) receptor.

Midazolam binds to a distinct, non-GABA binding site located on the GABA A receptor, specifically at the interface of the alpha and gamma subunits of this pentameric ligand-gated chloride ion channel. This allosteric interaction increases the affinity of the GABA A receptor for its endogenous inhibitory neurotransmitter, GABA.

Increased GABA binding enhances the frequency of GABA A receptor chloride channel opening. This facilitated influx of chloride ions ( Cl^-) into the postsynaptic neuron leads to hyperpolarization of the neuronal membrane. The resulting decreased neuronal excitability and reduction in action potential generation across broad CNS regions causes a system-level modulation characterized by generalized CNS depression and a reduction in neuronal firing synchronicity.

Dosage and Administration Information

How to Use BUCCOLAM: Official Administration Guidelines

BUCCOLAM is an oromucosal solution intended for single-dose emergency use by a trained parent or caregiver to manage acute convulsive seizures. The medicine is administered directly into the buccal cavity, which is the space between the gum and the inner cheek, using a pre-filled oral syringe. The administration route dictates that the full dose should be inserted slowly into this space; for larger volumes, the dose may be divided and administered to both sides of the mouth.

Standard Dosing Regimens

Dosage is standardized by age and corresponds to the contents of a single pre-filled syringe. This schedule must be followed precisely for this single-dose intervention.

Age Range	Dose
3 to < 1 year	2.5 mg
1 year to < 5 years	5 mg
5 years to < 10 years	7.5 mg
10 years to adults	10 mg

Administration Context and Frequency

BUCCOLAM is intended for a single administration only. Caregivers must not administer a second or repeat dose without first obtaining medical advice. The administration is time-sensitive: if the seizure does not stop within 10 minutes of the dose, emergency medical assistance must be sought immediately. For infants aged 3 to 6 months, official instructions mandate that administration must occur exclusively in a hospital setting where continuous monitoring and resuscitation equipment are available. No dose adjustment is required for patients with renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for BUCCOLAM

Evidence for Use in Prolonged Convulsive Seizures in Children and Adolescents

The primary body of research for oromucosal midazolam (BUCCOLAM) was built upon short-term Randomized Controlled Trials (RCTs). Studies were designed to examine oromucosal midazolam's application during acute, prolonged convulsive episodes in children and adolescents who have a diagnosis of epilepsy. Researchers focused on measuring how quickly visible seizure activity stopped after the medicine was given. Outcomes related to episodic or acute changes were monitored over defined time intervals.

Studies monitored for a measurement called outcomes related to seizure cessation, which tracks whether the seizure stopped quickly and did not return within a defined period, such as one hour. Studies were designed to compare time to seizure cessation measurements between oromucosal midazolam and rectal diazepam. Early research examined oromucosal midazolam against rectal diazepam, which served as the comparator in those trials. Research reports that the majority of the key studies used an open-label design.

Evidence for Administration in the Community Setting

Studies specifically explored the use of the buccal formulation in observational settings evaluating daily-life functioning, particularly its use by trained caregivers and parents in non-hospital environments. Research monitored how quickly and successfully the medicine could be administered in an emergency setting by non-professional personnel. Outcomes related to patient-reported outcomes describing perceived discomfort and caregiver preference were also examined. Comparative studies monitored and reported on caregiver preferences between the buccal and rectal routes of administration.

Evidence for Use in Adult Populations

Unlike the pediatric group, the evidence base for adults does not primarily consist of large Randomized Controlled Trials (RCTs). Instead, research for this population was supported by Pharmacokinetic (PK) bridging studies. These studies did not look at seizure outcomes directly but rather research examined how the drug is absorbed, distributed, and processed in the body. The research monitored the pharmacokinetic profile in adults and reported the measured parameters in comparison to the profile established in children. These findings provide the basis for extrapolation of data from the pediatric group to the adult population.

What Is Still Uncertain About BUCCOLAM Research

Several evidence gaps have been noted in the research landscape. Evidence quality varies across studies, particularly due to the design constraints of emergency medicine trials. There is a lack of comparative evidence against current preferred non-oral standards. Furthermore, Scientific reviews indicate that data for certain subgroups, such as patients with specific comorbid conditions or older adults with prolonged seizures, remain limited.

Key Studies & References Epilepsies: diagnosis and management (NICE guideline NG217)

Frequently Asked Questions (FAQ)

Common questions about BUCCOLAM (FAQ)

Q: Why is BUCCOLAM given into the cheek instead of being swallowed?

BUCCOLAM is given into the cheek, which is known as the buccal cavity, because this route allows the medicine to be absorbed quickly and directly into the bloodstream. This rapid absorption is considered essential for an emergency medicine to work fast. Official guidance notes that if the medicine is swallowed accidentally, the effects might not occur as quickly as intended.

Q: How quickly is BUCCOLAM expected to start working?

Studies and official clinical summaries indicate that the first observable effects of the medicine are often seen within approximately five minutes of administration. If the seizure does not stop within 10 minutes of the dose being administered, the regulatory guidelines specify that emergency medical help must be sought immediately.

Q: Does BUCCOLAM have potential interactions with common pain relievers?

Official documents note that the medicine interacts with strong pain relievers, particularly narcotic analgesics (opioids), which can increase the risk of heavy sedation and breathing problems. While non-narcotic pain relievers are not specifically listed, official regulatory documentation notes the need for caution when BUCCOLAM is used with any medicine that acts as a Central Nervous System (CNS) depressant.

Q: Can BUCCOLAM be used for breakthrough seizures in patients taking other antiepileptic drugs?

BUCCOLAM is indicated for the acute treatment of prolonged, convulsive seizures in patients who have a diagnosis of epilepsy. It may be used even if the patient is already taking other daily antiepileptic drugs. However, the regulatory documents caution that using it alongside other antiepileptic medicines may increase the risk of enhanced sedation or breathing difficulties.

Q: What is the reason why BUCCOLAM needs a specific way of storage?

Official storage instructions state that the product must be kept below 30 C and protected from light. Official requirements specify that the solution must not be refrigerated or frozen to help maintain the drug's stability and integrity. As with all medicines, the product is required to be kept out of the sight and reach of children.

Q: What is the difference between BUCCOLAM and other rectal seizure medicines?

BUCCOLAM is distinguished by its dosage form as an oromucosal solution given inside the cheek, while the other primary emergency seizure medicine (diazepam) is often administered rectally. Regulatory reviews comparing the two administration methods have reported that the buccal route is sometimes considered easier for caregivers and may show favorable outcomes related to the time to seizure cessation in children and adolescents.

Q: Why is midazolam the active ingredient in BUCCOLAM?

Midazolam is the chosen active ingredient due to its classification as a potent benzodiazepine derivative with a rapid onset of action. Regulatory studies show that it quickly enhances the natural calming process in the brain to stop seizure activity. Its relatively short duration of action is also a key factor for its use as an acute emergency treatment.

Q: Can BUCCOLAM be used for someone who has not been diagnosed with epilepsy?

The regulatory indication specifies that the medicine is for use only by parents or caregivers for a patient who has a documented diagnosis of epilepsy. The medicine is not indicated for the acute management of convulsions in persons without this diagnosis.

Q: Has BUCCOLAM received approval from major health authorities like the EMA or FDA?

BUCCOLAM has received marketing authorization from the European Medicines Agency (EMA) for the acute treatment of prolonged convulsive seizures. While the US Food and Drug Administration (FDA) has approved midazolam formulations for similar acute conditions, the BUCCOLAM oromucosal solution is specifically regulated by the EMA in Europe.

Q: Do children usually tolerate BUCCOLAM well?

Regulatory documents list several common effects, including somnolence (sleepiness), sedation, and headache. The safety profile is structured around the drug's Central Nervous System (CNS) depressant effect, and the most serious documented side effects are related to the respiratory system. For this reason, official guidance emphasizes that the patient is required to be kept under supervision by a trained caregiver after administration.

Q: What does the research say about BUCCOLAM in patients with kidney problems?

Official regulatory documents indicate that there are no specific efficacy studies of the medicine in children with chronic kidney failure. Because the elimination of midazolam may be delayed in these patients, the official documentation specifies that the medicine is for use with caution as the effects could be more prolonged.

Q: Does BUCCOLAM interact with medicines used to treat anxiety?

Yes, BUCCOLAM acts as a Central Nervous System (CNS) depressant, and medicines used to treat anxiety often fall into this category. Combining BUCCOLAM with other anxiolytic or sedative medicines may lead to an increased risk of heavy sedation, breathing difficulties, or profound drowsiness. This requires specific caution as outlined in the official product information.

Q: Does BUCCOLAM help stop all kinds of seizures?

According to regulatory documents, BUCCOLAM is specifically indicated for the acute treatment of prolonged, convulsive seizures (seizures that involve the body shaking). It is not indicated for non-convulsive seizures, which do not involve body shaking. Furthermore, it is a rescue medicine and is not intended for the prevention of future seizures.

Q: How long does the effect of BUCCOLAM usually last?

Midazolam, the active ingredient, is known for its relatively short duration of action. Official pharmacological data indicates that the half-life of the medicine in children is typically between 0.8 and 1.8 hours. This short duration is one reason it is chosen for immediate emergency intervention.

Q: Are there generic versions of BUCCOLAM available?

BUCCOLAM itself is classified as the proprietary medicinal product authorized for this specific buccal administration route for convulsive seizures. However, the active substance, midazolam, is a well-known substance that is available as a generic formulation in various other forms.

Q: What happens if BUCCOLAM is swallowed instead of given bucally?

If the medicine is swallowed accidentally, the official guidance is that it might not work as quickly or as effectively. This is because the drug is formulated specifically to be absorbed rapidly through the cheek lining, and absorption via the stomach is less efficient for this purpose.

Q: Is BUCCOLAM listed as a controlled substance in the US or UK?

Yes, the active ingredient, midazolam, is subject to strict regulatory control. It is classified as a Schedule IV controlled substance in the United States. In the United Kingdom and other regions, it is a Prescription-Only Medicine (POM) and may be subject to additional controlled drug protocols.

Q: Is it normal to see changes in heart rate after BUCCOLAM is administered?

Regulatory safety documents list changes in heart rhythm and blood pressure, such as bradycardia (slow heart rate) and hypotension (low blood pressure), as possible side effects. The rare occurrence of cardiac arrest is also documented. Official guidelines note that caregivers are responsible for continuing to monitor the patient’s breathing and circulation after administration.

Q: Do studies examine the long-term effects of BUCCOLAM use?

Official research and clinical trials for BUCCOLAM focus exclusively on its efficacy and safety for acute, short-term emergency use. The regulatory profile does not include long-term or maintenance therapy, and prolonged use of midazolam for seizure management is generally associated with risks like dependency.

Q: What does the patient information leaflet say about BUCCOLAM's side effects on the skin?

The official list of possible undesirable effects includes some skin reactions. Uncommon effects reported in regulatory documents include pruritus (itching), rash, and urticarial (hives). More serious reactions, such as swelling (angioedema), are listed in the 'Not Known' frequency category.

Q: Is there concern about using BUCCOLAM with allergy medicines or antihistamines?

There is a documented concern when BUCCOLAM is used with certain allergy medicines, especially those that act as Central Nervous System (CNS) depressants. This combination can lead to an increased risk of side effects, including enhanced sedation, deep drowsiness, or breathing difficulties. The official product information details the need for caution when combining BUCCOLAM with any such medicine.

Q: How does BUCCOLAM compare to intranasal midazolam in official records?

The official product documentation for BUCCOLAM primarily focuses on comparing its efficacy and ease of use against rectal diazepam. However, in broader clinical and regulatory reviews, both the buccal and intranasal midazolam administration routes are sometimes noted as being easier for caregivers to administer in emergency settings compared to the rectal route.

Q: Do people who take BUCCOLAM need to carry an official card or documentation?

Although there is no universal regulatory mandate for carrying a specific official card, healthcare providers often advise patients or caregivers to have an Emergency Medication Management Plan readily available. This plan typically documents the details of the patient’s epilepsy and the instructions for administering BUCCOLAM.

Q: Does the package insert for BUCCOLAM mention any effects on driving ability?

Yes, official product information includes explicit warnings about the effects on driving and operating machinery. Due to the sedative, memory-impairing, and muscle-relaxing effects of midazolam, Regulatory documents specify that patients must avoid driving or operating hazardous machinery until they are certain the effects of the medicine have completely worn off.

Q: Are there any reported interactions between BUCCOLAM and caffeine?

Caffeine is classified as a xanthine, and the official regulatory documents on midazolam's metabolism state that substances in the xanthine class can accelerate the elimination of benzodiazepines. The rate at which the body processes the medicine might be influenced by the presence of caffeine.

How should BUCCOLAM be stored and disposed of?

How to Store and Dispose of BUCCOLAM?

The official storage and disposal requirements for BUCCOLAM are strictly defined by regulatory authorities to maintain the stability of the midazolam solution and ensure environmental safety.

Storage Conditions

The medicine must be stored below 30 C and kept protected from light. It is explicitly stated that the product must not be refrigerated or frozen. The oromucosal solution must remain in its original blister pack and protective plastic tube until the moment of use. A mandatory child safety rule requires that this medicine be kept out of the sight and reach of children.

Disposal Instructions

To prevent environmental contamination, BUCCOLAM must not be thrown away with household waste or disposed of via wastewater. Unused or expired medication must be returned to a pharmacist or an authorized pharmaceutical waste collection point for proper disposal, following local regulations.

BUCCOLAM